IP Library Granted Patent US 8,840,877
Granted Patent B2
US 8,840,877 · App. 12/999,076 · Granted Sep 23, 2014

Polysaccharide-protein conjugates reversibly coupled via imine bonds

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,840,877
App. No.
12/999,076
Granted
Sep 23, 2014
Kind
B2
Abstract

Method for preparing an oxidized polysaccharide-protein composition, by (a) oxidizing a polysaccharide with an oxidizing agent to form an oxidized polysaccharide where less than 20% of the oxidized units are comprised of alpha-hydroxy aldehyde units, (b) reacting the oxidized polysaccharide with a protein to form a composition comprising an oxidized polysaccharide-protein conjugate, and (c) maintaining the oxidized polysaccharide-protein conjugate composition by placing it in an environment where the temperature is less than 8° C. The oxidized polysaccharide and the protein are conjugated via one or more imine bonds, the oxidized polysaccharide-protein composition is soluble in aqueous solvent, and the composition is capable of releasing the protein.

Claims (31)

1. A method of preparing an oxidized polysaccharide-protein composition comprising the steps of:

(a) oxidizing a polysaccharide with an alkali metal periodate compound to form an oxidized polysaccharide where less than 20% of the oxidized units are comprised of alpha-hydroxy aldehyde units;

(b) reacting the oxidized polysaccharide with a protein in the absence of a reducing agent to form a composition comprising an oxidized polysaccharide-protein conjugate,

(c) subjecting the oxidized polysaccharide-protein conjugate to dialysis;

(d) subjecting the dialyzed polysaccharide-protein conjugate to sterile filtration to allow for administration to a human or animal;

the oxidized polysaccharide and the protein being conjugated via one or more imine bonds which are not subjected to reduction;

the oxidized polysaccharide-protein composition being soluble in aqueous solvent;

the composition being capable of releasing the protein.

2. A method according to claim 1 , wherein the polysaccharide is selected from cellulose, pectin, starch and hydroxyhydrocarbyl derivatives thereof.

3. A method according to claim 1 , wherein the polysaccharide is selected from cellulose, pectin, starch, hydroxyalkyl cellulose and hydroxyalkyl starch.

4. A method according to claim 1 , wherein the polysaccharide is hydroxyethyl starch.

5. A method according to claim 1 , wherein the degree of oxidation of the oxidized polysaccharide is from 1 to 100%.

6. A method according to claim 1 , wherein the weight average molecular weight of the polysaccharide is from 1 to 2000 kDa.

7. A method according to claim 1 , wherein the ratio of oxidized polysaccharide to protein is from 0.1:1 to 20:1.

8. A method according to claim 1 , wherein the oxidized polysaccharide is reacted with a protein in step (b) in the presence of at least one further protein such that the oxidized polysaccharide-protein composition comprises more than one protein and each protein is conjugated to the oxidized polysaccharide via one or more imine bonds.

9. A method according to claim 1 , wherein the or each protein is selected from antibodies, cytokines, enzymes, growth factors and regulatory proteins.

10. A method according to claim 1 , wherein the or each protein is selected from erythropoietin (EPO), granulocyte-colony stimulating factor (G-CSF), uricase, beta-glucocerebrosidase, alpha-galactosidase, C-1 inhibitor, streptokinase, DNAseI, alpha-1 antitrypsin, asparaginase, arginine deiminase, Factor IX, Factor VIIa, Factor VIII, Factor IIa (thrombin), anti-TNF-alpha antibody, tissue plasminogen activator, human growth hormone, superoxide dismutase, catalase, CD163 antibody, anti-VEGF, anti-thrombin antibody, anti-CD20 antibody, anti-IgG1 antibody, anti-HER2 antibody, anti-CD33 antibody, anti-IgG2a antibody, anti-EGFR antibody, histone, interferon, insulin, albumin and mixtures thereof.

11. A method according to claim 1 , wherein the oxidized polysaccharide-protein conjugate is less than 0.1 μm in size.

12. A method according to claim 1 , wherein the protein has a weight average molecular weight of greater than about 1 kDa.

13. A method according to claim 1 , wherein the oxidized polysaccharide is reacted with a protein in step (b) in the absence of a molecular crowding agent.

14. A method according to claim 1 , wherein the oxidized polysaccharide-protein composition further comprises nonconjugated protein.

15. A method of reversibly conjugating a protein to an oxidized polysaccharide comprising the steps of preparing an oxidized polysaccharide-protein composition according to claim 1 , and dissolving the oxidized polysaccharide-protein composition in a solvent.

16. A method according to claim 1 , wherein the polysaccharide has less than 15% 1,2,3-triol content.

17. A method according to claim 1 wherein the polysaccharide has less than 5% 1,2,3-triol content.

18. A method according to claim 1 wherein the polysaccharide has less than 1% 1,2,3-triol content.

19. A method according to claim 1 , wherein the ratio of oxidized polysaccharide to protein is 1:1 molar equivalents of polysaccharide relative to protein.

20. A method according to claim 1 , wherein the ratio of oxidized polysaccharide to protein is 0.1:1 molar equivalents of polysaccharide relative to protein.

21. A method according to claim 1 , wherein the ratio of oxidized polysaccharide to protein is 10:1 molar equivalents of polysaccharide relative to protein.

22. A method according to claim 1 , wherein the degree of oxidation of the oxidized polysaccharide is 100%.

23. A method according to claim 1 , wherein step (b) is carried out at a pH of 6-8.

24. A method according to claim 1 , wherein step (a) is carried out at a temperature of less than 20° C. and step (b) is carried out at a temperature of at least 5° C.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Oct 21, 2020
From: MIDCAP FINANCIAL TRUST
To: THERAPURE BIOPHARMA INC.
Reel/Frame 054123/0837 →
SECURITY INTEREST Recorded Nov 23, 2015
From: THERAPURE BIOPHARMA INC.
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 037116/0471 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 18, 2012
From: ADAMSON, GORD; BELL, DAVID; BROOKES, STEVEN
To: THERAPURE BIOPHARMA INC.
Reel/Frame 028394/0946 →